Table 2. Multivariate Analysis* for Survival, Progression-Free Survival, and Relapse/Progression.
| Overall Survival | ||
|---|---|---|
| Relative Risk of Death (95% CI) | P-Value | |
| Conditioning regimen | ||
| Myeloablative | 1.0 | |
| Nonmyeloablative | 0.7 (0.4-1.1) | .14 |
| Donor type | ||
| Matched related | 1.0 | |
| Unrelated/mismatched related | 2.9 (1.6-5.3) | <.01 |
| Umbilical cord blood | 1.4 (0.8-2.6) | .41 |
| Progression-Free Survival | ||
|---|---|---|
| Relative Risk of Death or Progression/Relapse (95% CI) | P-Value | |
| Conditioning regimen | ||
| Myeloablative | 1.0 | |
| Nonmyeloablative | 0.7 (0.4-1.2) | .24 |
| Donor type | ||
| Matched related | 1.0 | |
| Unrelated/mismatched related | 2.4 (1.4-4.4) | <.01 |
| Umbilical cord blood | 1.4 (0.8-2.4) | .29 |
| Diagnosis | ||
| NHL | 1.0 | |
| Hodgkins | 1.9 (1.1-3.2) | .03 |
| Disease status | ||
| CR1+ | 1.0 | |
| PR1+ | 0.8 (0.4-1.6) | .39 |
| Minimally responsive disease | 1.9 (0.9-4.1) | .09 |
| Relapse/Progression | ||
|---|---|---|
| Relative Risk of Relapse or Disease Progression (95% CI) | P-Value | |
| Conditioning regimen | ||
| Myeloablative | 1.0 | |
| Nonmyeloablative | 3.3 (1.2-9.2) | .03 |
| Donor type | ||
| Matched related | 1.0 | |
| Unrelated/mismatched related | 1.1 (0.4-3.2) | .88 |
| Umbilical cord blood | 2.1 (0.9-5.1) | .10 |
CI indicates confidence interval; NHL, non-Hodgkin’s lymphoma; CR, complete remission; PR, partial remission.
*
The above models are the result of multiple regression analysis after testing the following variables: age, weight, gender, donor type, CMV serostatus, acute GVHD (time-dependent variable), year of transplant (1997-2000 versus 2001-2004), diagnosis, and disease status. Conditioning intensity, as the main effect variable, is presented in every model. Otherwise, only factors with at least marginal significance are reported.